Skip to content
Screener

Krystal Biotech, Inc. KRYS Financing Cash Flow

Financing Cash Flow at other companies

Sarepta Therapeutics, Inc. logo
Sarepta Therapeutics, Inc.SRPT
$241K-98.1%
Ultragenyx Pharmaceutical logo
Ultragenyx PharmaceuticalRARE
$394.19M+13,285%
BridgeBio Pharma logo
BridgeBio PharmaBBIO
$549.89M+812%
Viridian Therapeutics, Inc. logo
Viridian Therapeutics, Inc.VRDN
$325.12M+42,455%
Regenxbio logo
RegenxbioRGNX
$17.57M-87.4%
Zevra Therapeutics, Inc. logo
Zevra Therapeutics, Inc.ZVRA
-$52.8M-3,386%

Other financials

Income statement

See full
Revenue$116.4M+31.9%
Operating income$53.7M+48.1%
Net income$55.9M+56.5%
EPS (diluted)$1.83+52.5%

Balance sheet

See full
Cash & equivalents$501.3M+62.4%
Total debt$9.1M-5.7%
Total equity$1.3B+29.7%
Total assets$1.4B+30.0%

Cash flow

See full
Operating cash flow$80.4M+160%
CapEx$7.1M+15.2%
Free cash flow$73.2M+196%

Valuation

See full
Market cap$9.64B+145%
Enterprise value$9.15B+155%
P/E42.9×+16.0×
P/S23.1×+12.2×

Profitability

See full
Operating margin42.8%+10.2pp
Net margin53.9%+16.7pp
FCF margin56.9%+16.5pp

Returns & leverage

See full
Return on equity19.9%+6.0pp
Debt / equity0.0×
Current ratio9.5×-0.2×

Where this comes from

Reported directly by Krystal Biotech, Inc. in its filing.

Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInFinancingActivities.

The source filing: Krystal Biotech, Inc.’s 10-Q, filed May 4, 2026.

Filed
May 4, 2026, 7:06 AM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001711279-26-000043
(in thousands)Three Months Ended March 31, 2026Three Months Ended March 31, 2025
Proceeds from exercise of stock options6,5011,462
Taxes paid for employee tax withholding related to restricted stock units(16,960)(12,116)
Taxes paid related to settlement of restricted stock awards(1,812)
Net cash (used in) financing activities(10,459)(12,466)
Effect of exchange rate changes on cash and cash equivalents(1,331)171
Net increase (decrease) in cash and cash equivalents5,009(36,095)
Cash and cash equivalents at beginning of period496,304344,865
Cash and cash equivalents at end of period$501,313$308,770

ITEM 1. FINANCIAL STATEMENTS

FAQ

What is Krystal Biotech, Inc.'s financing cash flow?
Krystal Biotech, Inc. (KRYS) reported financing cash flow of -$10.46M in Q1 2026.
How has Krystal Biotech, Inc.'s financing cash flow changed year-over-year?
Krystal Biotech, Inc.'s financing cash flow increased by 16.1% year-over-year, from -$12.47M to -$10.46M.
What is the long-term trend for Krystal Biotech, Inc.'s financing cash flow?
Over 3 years (2021 to 2024), Krystal Biotech, Inc.'s financing cash flow has grown at a -57.3% compound annual growth rate (CAGR), from $347.88M to $27.01M.
What does financing cash flow mean?
Total net cash provided by or used in financing activities — debt issuance/repayment, equity transactions, and dividend payments.

Ask your AI about Krystal Biotech, Inc.'s financing cash flow.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude